Results 111 to 120 of about 84,249 (293)

From cramming to binge‐watching: Integrating documentary‐based assessment into a pharmacology and toxicology curriculum—a qualitative study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims In the context of pharmacology and toxicology education, there is a growing shift toward programmatic assessment models that prioritize longitudinal learning, reflection and development of higher‐order cognitive skills. As part of this transition, we are exploring alternative and more meaningful forms of assessment. This qualitative study
Narin Akrawi   +2 more
wiley   +1 more source

Current practices on external quality assurance of academic recognition among QA agencies

open access: yes, 2017
The fair recognition1 of qualifications, periods of study, and prior learning (to which we will refer in this report as “recognition for academic purposes” or “academic recognition”) has been one of the main objectives of the Bologna Process since its ...
Sánchez Chaparro, Teresa   +9 more
core  

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Grounded QA

open access: yes
Grounded Question-Answering (Grounded ...
Ioannis Kourouklides
core   +1 more source

Automated methods for Question-Answering in Icelandic

open access: yes, 2021
Question Answering (QA) is the automated task of providing an answer to a question posed in human language. Whether through search engines or speech controlled home assistants it has become a tightly integrated part of many peoples' daily routine at work
Vésteinn Snæbjarnarson 1988-
core  

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

ความคิดเห็นและการปฏิบัติของคณาจารย์ในการใช้ระบบประกันคุณภาพการศึกษาเครือข่ายมหาวิทยาลัยอาเซียน (AUN-QA) ระดับหลักสูตรในประเทศไทย

open access: yes, 2019
การศึกษาครั้งนี้มีวัตถุประสงค์เพื่อสำรวจความคิดเห็นและการปฏิบัติของอาจารย์ในการประกันคุณภาพการศึกษาระดับหลักสูตร ด้วยระบบประกันคุณภาพเครือข่ายมหาวิทยาลัยอาเซียน (AUN-QA) รวบรวมข้อมูลด้วยแบบสอบถามระหว่างวันที่ 16 พฤศจิกายน ถึง 25 ธันวาคม พ.ศ.
อนุวงศ์, กัญญดา   +3 more
core  

Monitoring Daily QA 3 constancy for routine quality assurance on linear accelerators

open access: yes, 2016
The purpose of this study was to evaluate the suitability of the Daily QA 3 (Sun Nuclear Corporation, Melbourne, USA) device as a safe quality assurance device for control of machine specific parameters, such as linear accelerator output, beam quality ...
Binny, Diana   +4 more
core   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Home - About - Disclaimer - Privacy